In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...
Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus ...
We recently published a list of 10 Stocks Grow Firmer Despite Mixed Market Sentiment. In this article, we are going to take a ...
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
Bristol-Myers saw its share prices grow by 3.67 percent on Monday to finish at $57.88 apiece as investors cheered news of the ...
KEYTRUDA monotherapy is the recommended first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression, ...
The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.
Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...
The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as a first-line therapy for patients with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback